Journal of Clinical Oncology · 2015 · 114 citations · 13 references
MedicineOncologyPharmacologyCancer PharmacologyChemotherapyGynecologic OncologyEndometrial CancerGynecologic Cancer PharmacotherapyHormonal TherapyMetastatic Cancer ManagementToxicity ManagementDrug DiscontinuationEndometrial Cancer ChemotherapyMtor InhibitionMtor SignalingPi3k-akt-mtor SignalingProgressive Disease AssessmentRecurrent Disease TherapyTreatment Discontinuation Rates
PURPOSE: The prognosis for women with recurrent and metastatic endometrial cancer is poor, and improved therapies are needed. The mammalian target of rapamycin (mTOR) pathway is an important target, and mTOR inhibitors show clinical activity in endometrial cancer. PATIENTS AND METHODS: An open-label, multicenter, randomized, phase II trial of oral ridaforolimus compared with progestin or investigator choice chemotherapy (comparator) was undertaken in women with metastatic or recurrent endometrial cancer who had progressive disease following one or two lines of chemotherapy and no hormonal therapy. The primary end point was progression-free survival (PFS) assessed by independent radiologic review. RESULTS: One hundred thirty patients were enrolled (64 received ridaforolimus and 66 received the comparator), and median age was 66 years. Treatment discontinuation as a result of adverse events was 33% with ridaforolimus versus 6% with the comparator, with common (> 10%) grade 3 toxicities being hyperglycemia, anemia, and diarrhea. Thirty-eight percent (ridaforolimus) versus 71% (comparator) of patients discontinued treatment as a result of disease progression. Median PFS at the protocol prespecified interim analysis with 58 PFS events (primary end point) was 3.6 months (95% CI, 2.7 to 7.3 months) for ridaforolimus and 1.9 months (95% CI, 1.9 to 2.3 months) for the comparator (hazard ratio, 0.53; 95% CI, 0.31 to 0.90; P = .008). PFS rate for ridaforolimus versus comparator was 48% versus 18% at 16 weeks and 38% versus 15% at 24 weeks. Objective response rate for ridaforolimus versus comparator was 0% versus 4% (P = .925), and stable disease was achieved in 35% versus 17% of patients (P = .021). CONCLUSION: Oral ridaforolimus shows encouraging activity in advanced endometrial cancer but is associated with significant toxicity. Inhibition of the PI3K/Akt/mTOR pathway may be a viable therapeutic target.
13
Two pathogenetic types of endometrial carcinoma
Jan V. Bokhman · Gynecologic Oncology · 1983 · 2.5K citations
Medicine, Gynecology, Oncology +13
Marcus E. Randall, Virginia L. Filiaci, Hyman B. Muss et al. · Journal of Clinical Oncology · 2005 · 870 citations · Full text
Medicine, Gynecology, Oncology +10
Gini F. Fleming, Virginia L. Brunetto, David Cella et al. · Journal of Clinical Oncology · 2004 · 567 citations · Full text
Medicine, Oncology, Pharmacology +17